In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Keywords: پدری; BRCA1/2; BRCA1 or BRCA2; CDK; cyclin-dependent kinase; FBS; heat-inactivated fetal bovine serum; HGSOC; high-grade serous ovarian carcinoma; HR; homologous recombination; IP; intraperitoneal; pADPr; poly(ADP-ribose) polymer; PARP; poly(ADP-ribose) polymer